Retrospective analysis compares liraglutide and DPP-4 inhibitor effectiveness, safety in European Type 2 Diabetes patients
Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe
Abstract
Retrospective data collection in Europe aimed to compare the real-world effectiveness and safety of liraglutide versus DPP-4 inhibitors in Type 2 Diabetes patients over 12 months.